Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Boissel

Showing results (1-10 of 242) with videos related to

Pageof 25
Sort By:
Best Practice & Research. Clinical Haematology|October 21, 2017
How should we treat the AYA patient with newly diagnosed ALL?Nicolas Boissel
Hematology. American Society of Hematology. Education Program|December 9, 2022
New developments in ALL in AYANicolas Boissel
The Lancet. Haematology|December 22, 2023
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?Nicolas Boissel
Blood|January 28, 2021
ALL in escape roomNicolas Boissel
Hematology. American Society of Hematology. Education Program|December 5, 2025
Where do immunotherapies stand in management of acute leukemia in adults?Nicolas Boissel
La Revue Du Praticien|March 22, 2006
[Acute leukemia. First part--acute myeloblastic leukemia:diagnosis, clinical course]Nicolas Boissel, Hervé Dombret
Blood|June 14, 2018
Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?Nicolas Boissel, André Baruchel
Bulletin Du Cancer|September 28, 2020
[ALL in adult patients: Contribution and limits of pediatric management]Florence Rabian, Nicolas Boissel
Bulletin Du Cancer|June 4, 2017
[Adolescents and young adults with acute lymphoblastic leukemia. A specific management]Nicolas Boissel, Stéphane Ducassou
Blood|April 6, 2019
Should young adults with ALL be treated as children?Hervé Dombret, Nicolas Boissel
Pageof 25

Showing results (1-10 of 242) with videos related to

Sort By:
Pageof 25
Best Practice & Research. Clinical Haematology|October 21, 2017
How should we treat the AYA patient with newly diagnosed ALL?Nicolas Boissel
Hematology. American Society of Hematology. Education Program|December 9, 2022
New developments in ALL in AYANicolas Boissel
The Lancet. Haematology|December 22, 2023
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?Nicolas Boissel
Blood|January 28, 2021
ALL in escape roomNicolas Boissel
Hematology. American Society of Hematology. Education Program|December 5, 2025
Where do immunotherapies stand in management of acute leukemia in adults?Nicolas Boissel
La Revue Du Praticien|March 22, 2006
[Acute leukemia. First part--acute myeloblastic leukemia:diagnosis, clinical course]Nicolas Boissel, Hervé Dombret
Blood|June 14, 2018
Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children?Nicolas Boissel, André Baruchel
Bulletin Du Cancer|September 28, 2020
[ALL in adult patients: Contribution and limits of pediatric management]Florence Rabian, Nicolas Boissel
Bulletin Du Cancer|June 4, 2017
[Adolescents and young adults with acute lymphoblastic leukemia. A specific management]Nicolas Boissel, Stéphane Ducassou
Blood|April 6, 2019
Should young adults with ALL be treated as children?Hervé Dombret, Nicolas Boissel
Pageof 25